Oncotarget Is Revolutionizing The Way Information About Cancer Is Being Shared
Oncotarget is a multidisciplinary, international weekly peer-reviewed traditional open access medical journal that covers everything related to oncology. Special focus is given to potential therapy targets, treatments that improve the management of cancer patients, and the pathological aspects of different cancers. New therapies, protocols,cancer management programs, and the patient’s points of view as well as quality of life is also covered. The journal is incredibly successful in the way it makes scientific results quickly available to a wide audience that can share it even further. Each paper or issue of the journal can be printed or viewed online.
The meaning behind the name Oncotarget speaks to the fact that it is a publication that covers information about all pathways, molecules, neurodegeneration and atherosclerosis, cellular functions related to aging and cancer, neurons and lymphocytes, microbes, and cancer cells.The journal excels at breaking down the borders between different cancer specialties and helps to tie together biomedical science from differing fields. It is lead and carried by some of the most prestigious scientists in the world, and the goal of the journal is to create a world without disease.Oncotarget is a member of and believes in the philosophy and practices laid out by the Committee on Publication Ethics (COPE), which was established in 1997 to promote the Code and Conduct and Best Practice Guidelines for Journal Editors.
Its papers are also indexed on Science Citation Index Expanded (also known as SciSearch®), PubMed and PubMed Central, Journal Citation Reports/Science Edition, BIOSIS Previews, Biological Abstracts, Embase, Scopus, Directory of Open Access Journals (DOAJ), and OAIster: The Open Access Initiative.The future of Cancer research and the sharing of information that different experts in separate fields are discovering about it is looking bright, and Oncotarget hopes to continue to be a part of these efforts. At no other time in history has a journal like Oncotarget been able to reach the size of the audience it has access to now. Whether it is through the internet or live conferences, cancer patients and those who treat them can benefit from the information sharing that Oncotarget is helping to facilitate.